Stock GUD KNIGHT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
5.73 CAD +0.70% Intraday chart for Knight Therapeutics Inc. +0.17% +10.40%
Mar. 22 Knight Therapeutics Price Target Raised to $7 at RBC MT
Mar. 21 Knight Therapeutics Reports Fourth Quarter Results MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GL
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
GL
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
GL
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
GL
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
GL
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
AQ
Knight Therapeutics Inc. Celebrates its First Decade of Success
GL
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
GL
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
AQ
Knight Therapeutics Announces Launch of Bijuva® in Canada
GL
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
GL
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada
GL
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada
AQ
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
GL
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
AQ
Knight Therapeutics Reports Third Quarter 2023 Results
GL
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
GL
Notice of Knight Therapeutics' Third Quarter 2023 Results Conference Call
AQ
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
GL
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GUD Stock
  4. News Knight Therapeutics Inc.
  5. Press Releases